EMA Authorised: Cervarix (human papillomavirus1 type 16 L1 protein;human papillomavirus type 18 L1 protein) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

The European Medicines Agency authorised Cervarix, an HPV vaccine targeting types 16 and 18, for immunization to prevent papillomavirus infections and cervical …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Dysplasia
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Status: Authorised. Therapeutic area: Papillomavirus Infections;Uterine Cervical Dysplasia;Immunization. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 26/04/2023